Literature DB >> 26369685

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Induced Dyspepsia.

Paul Ray-Yee Yap, Khean-Lee Goh1.   

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most prescribed group of drugs in the world. They are used primarily for pain relief in chronic inflammatory joint disease and act by inhibiting enzymes COX1 and COX2 and ultimately preventing the production of active prostanoids which are required for the innate inflammatory pathway. The use of NSAIDs have been associated with the development of gastrointestinal (GI) symptoms ranging from simple dyspepsia to life threatening GI bleeds and perforations. The definition of dyspepsia has evolved over the years and this has hampered accurate studies on the prevalence of dyspepsia as different studies used varying criteria to define dyspepsia. It is now known that NSAIDs significantly increase the risk of dyspepsia.The risk of developing peptic ulcer disease vary with specific NSAIDs and dosages but there is no correlation between the symptoms of dyspepsia and underlying peptic ulcers. The pathogenesis of dyspepsia with NSAIDs is not completely understood. Peptic ulceration alone is not able to account for the majority of dyspepsia symptoms encountered by NSAIDs users. Erosive oesophagitis secondary to NSAIDs may be contributing factor to the prevalence of dyspepsia in NSAIDs users. Altered gut permeability and changes in gastric mechanosensory function due to NSAIDs may also be a contributory factor. Management of NSAID induced dyspepsia is involves a multipronged approach. Drug avoidance if possible would be ideal. Other options include using the lowest effective dose, changing to an NSAIDs with a safer GI risk profile, avoiding concurrent use with other NSAIDs or if the patient has a previous history of peptic ulcer disease, and co-prescribing with anti-secretory medications such as proton pump inhibitors. Eradication of Helicobacter pylori has a protective role against developing peptic ulcers and may also improve symptoms of NSAIDs induced dyspepsia.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26369685     DOI: 10.2174/1381612821666150915105738

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  6 in total

1.  Factors Related to Upper Gastrointestinal Symptom Generation in 2275 Helicobacter pylori Seroprevalent Adults.

Authors:  Sang Pyo Lee; Sun-Young Lee; Jeong Hwan Kim; In-Kyung Sung; Hyung Seok Park; Chan Sup Shim
Journal:  Dig Dis Sci       Date:  2017-03-09       Impact factor: 3.199

Review 2.  Effects of Non-Opioid Analgesics on the Cell Membrane of Skin and Gastrointestinal Cancers.

Authors:  Natalia Janicka; Agnieszka Sałek; Magdalena Sawińska; Ernest Kuchar; Anna Wiela-Hojeńska; Katarzyna Karłowicz-Bodalska
Journal:  Int J Mol Sci       Date:  2022-06-26       Impact factor: 6.208

3.  Risk Factors for the Presence of Symptoms in Peptic Ulcer Disease.

Authors:  Sang Pyo Lee; In-Kyung Sung; Jeong Hwan Kim; Sun-Young Lee; Hyung Seok Park; Chan Sup Shim
Journal:  Clin Endosc       Date:  2016-12-23

4.  Survey on the prevalence of dyspepsia and practices of dyspepsia management in rural Eastern Uganda.

Authors:  Yang Jae Lee; Gautam Adusumilli; Francis Kyakulaga; Peter Muwereza; Rauben Kazungu; Timothy Scott Blackwell; Jose Saenz; Moonkyung Cho Schubert
Journal:  Heliyon       Date:  2019-06-13

5.  Assessing the Anti-inflammatory Mechanism of Reduning Injection by Network Pharmacology.

Authors:  Fuda Xie; Mingxiang Xie; Yibing Yang; Miaomiao Zhang; Xiaojie Xu; Na Liu; Wei Xiao; Jiangyong Gu
Journal:  Biomed Res Int       Date:  2020-12-16       Impact factor: 3.411

6.  Nonsteroidal Anti-Inflammatory Drug Prescriptions Are Associated With Increased Stress Fracture Diagnosis in the US Army Population.

Authors:  Julie M Hughes; Craig J McKinnon; Kathryn M Taylor; Joseph R Kardouni; Lakmini Bulathsinhala; Katelyn I Guerriere; Kristin L Popp; Mary L Bouxsein; Susan P Proctor; Ronald W Matheny
Journal:  J Bone Miner Res       Date:  2018-12-10       Impact factor: 6.741

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.